{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T18:39:30Z","timestamp":1784659170969,"version":"3.55.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T00:00:00Z","timestamp":1682985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T00:00:00Z","timestamp":1682985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s40273-023-01272-9","type":"journal-article","created":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T10:02:17Z","timestamp":1683021737000},"page":"857-867","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Oral Azacitidine for Maintenance Treatment of Acute Myeloid Leukaemia After Induction Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1007-4284","authenticated-orcid":false,"given":"Willem","family":"Witlox","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Grimm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Howick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Ahmadu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"McDermott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Otten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caro","family":"Noake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Wolff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Joore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,2]]},"reference":[{"key":"1272_CR1","unstructured":"Celgene Ltd. Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy [ID3892]: Document B (v2.0). Submission to National Institute of Health and Care Excellence. Single technology appraisal (STA); 2022. Accessed 11 Jan 2022."},{"key":"1272_CR2","volume-title":"Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy [ID3892]: a Single Technology Assessment","author":"J Howick","year":"2022","unstructured":"Howick J, Witlox W, Ahmadu C, Grimm S, Armstrong N, McDermott K, et al. Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy [ID3892]: a Single Technology Assessment. York: Kleijnen Systematic Reviews Ltd; 2022."},{"key":"1272_CR3","unstructured":"National Institute for Health and Care Excellence. Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy: NICE technology appraisal guidance 827 [Internet]. London: NICE; 2022. https:\/\/www.nice.org.uk\/guidance\/ta827. Accessed 13 Jan 2023."},{"key":"1272_CR4","unstructured":"National Institute for Health and Care Excellence. Single Technology Appraisal: Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy [ID3892]: Committee Papers [Internet]. London: NICE; 2022. https:\/\/www.nice.org.uk\/guidance\/ta827\/evidence\/appraisal-consultation-committee-papers-pdf-11246852557. Accessed 13 Jan 2023."},{"key":"1272_CR5","unstructured":"National Institute for Health and Care Excellence. Health Technology Appraisal: Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy: final scope [Internet]. London: NICE; 2021. https:\/\/www.nice.org.uk\/guidance\/gid-ta10775\/documents\/final-scope. Accessed 7 Dec 2021."},{"key":"1272_CR6","unstructured":"National Institute for Health and Care Excellence. Midostaurin for untreated acute myeloid leukaemia: NICE technology appraisal guidance 523 [Internet]. London: NICE; 2018. https:\/\/www.nice.org.uk\/guidance\/ta523. Accessed 29 Nov 2021."},{"key":"1272_CR7","first-page":"25","volume-title":"Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy [ID3892]: clarification letter","author":"National Institute for Health and Care Excellence","year":"2022","unstructured":"National Institute for Health and Care Excellence. Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy [ID3892]: clarification letter. London: NICE; 2022. p. 25."},{"key":"1272_CR8","unstructured":"Celgene Ltd. Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy [ID3892]: response to request for clarification from the ERG (v3.0); 2022: 249. Accessed 10 Feb 2022."},{"issue":"Suppl 2","key":"1272_CR9","first-page":"LBA-3","volume":"134","author":"AH Wei","year":"2020","unstructured":"Wei AH, D\u00f6hner H, Pocock C, Montesinos P, Afanasyev B, Dombret H, et al. The QUAZAR AML-001 maintenance trial: results of a phase III international, randomized, double-blind, placebo-controlled study of CC-486 (oral formulation of azacitidine) in patients with acute myeloid leukemia (AML) in first remission. Blood. 2020;134(Suppl 2):LBA-3.","journal-title":"Blood"},{"issue":"Suppl 2","key":"1272_CR10","doi-asserted-by":"publisher","first-page":"LBA-3","DOI":"10.1182\/blood-2019-132405","volume":"134","author":"A Wei","year":"2019","unstructured":"Wei A, Dohner H, Pocock C, Montesinos P, Afanasyev B, Dombret H, et al. The QUAZAR AML-001 maintenance trial: results of a phase III international, randomized, double-blind, placebo-controlled study of CC-486 in Patients with acute myeloid leukemia (AML) in first remission. Blood. 2019;134(Suppl 2):LBA-3.","journal-title":"Blood"},{"issue":"9","key":"1272_CR11","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1038\/s41375-021-01179-4","volume":"35","author":"RA Larson","year":"2021","unstructured":"Larson RA, Mandrekar SJ, Huebner LJ, Sanford BL, Laumann K, Geyer S, et al. Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603\/RATIFY trial. Leukemia. 2021;35(9):2539\u201351.","journal-title":"Leukemia"},{"key":"1272_CR12","unstructured":"National Institute for Health and Care Excellence. Liposomal cytarabine\u2013daunorubicin for untreated acute myeloid leukaemia: NICE technology appraisal guidance 552 [Internet] London: NICE; 2021. https:\/\/www.nice.org.uk\/guidance\/ta552. Accessed 27 Jan 2022."},{"issue":"1","key":"1272_CR13","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s40273-018-0704-8","volume":"37","author":"N Joshi","year":"2019","unstructured":"Joshi N, Hensen M, Patel S, Xu W, Lasch K, Stolk E. Health state utilities for acute myeloid leukaemia: a time trade-off study. Pharmacoeconomics. 2019;37(1):85\u201392.","journal-title":"Pharmacoeconomics"},{"key":"1272_CR14","unstructured":"Department of Health and Social Care. Drugs and pharmaceutical electronic market information tool (eMIT) [Database]. London: NHS; 2021. https:\/\/www.gov.uk\/government\/publications\/drugs-and-pharmaceutical-electronic-market-information-emit. Accessed 2 Feb 2022."},{"key":"1272_CR15","unstructured":"NHS. NHS reference costs 2015 to 2016 [online]. https:\/\/www.gov.uk\/government\/publications\/nhs-reference-costs-2015-to-2016."},{"key":"1272_CR16","volume-title":"British National Formulary (BNF82)","author":"Joint Formulary Committee","year":"2021","unstructured":"Joint Formulary Committee. British National Formulary (BNF82). London: BMJ Group and Pharmaceutical Press; 2021."},{"key":"1272_CR17","unstructured":"FDA. VIDAZA (azacitidine) US Prescribing Information; 2008. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/050794s011lbl.pdf. Accessed 3 March 2020. Updated 21 Aug 2008."},{"key":"1272_CR18","volume-title":"Exploring the cost of care at the end of life","author":"T Georghiou","year":"2014","unstructured":"Georghiou T, Bardsley M, Georghiou T, Bardsley M. Exploring the cost of care at the end of life. London: Nuffield Trust; 2014."},{"key":"1272_CR19","unstructured":"Curtis LA, Burns A. Unit costs of health & social care 2020 [Internet]. Canterbury: PSSRU, University of Kent; 2020. https:\/\/kar.kent.ac.uk\/84818\/. Accessed 7 Dec 2021."},{"issue":"Suppl 6","key":"1272_CR20","doi-asserted-by":"publisher","first-page":"vi138","DOI":"10.1093\/annonc\/mdt320","volume":"24","author":"MF Fey","year":"2013","unstructured":"Fey MF, Buske C. Acute myeloblastic leukaemias in adult patients: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi138\u201343.","journal-title":"Ann Oncol"},{"key":"1272_CR21","unstructured":"Latimer N. NICE DSU Technical Support Document 14: survival analysis for economic evaluations alongside clinical trials\u2014extrapolation with patient-level data [online]. National Institute for Health and Care Excellence (NICE). http:\/\/nicedsu.org.uk\/wp-content\/uploads\/2016\/03\/NICE-DSU-TSD-Survival-analysis.updated-March-2013.v2.pdf."},{"key":"1272_CR22","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12962-018-0153-4","volume":"16","author":"G Tremblay","year":"2018","unstructured":"Tremblay G, Dolph M, Patel S, Brandt P, Forsythe A. Cost-effectiveness analysis for midostaurin versus standard of care in acute myeloid leukemia in the United Kingdom. Cost Eff Resour Alloc. 2018;16:33.","journal-title":"Cost Eff Resour Alloc"},{"key":"1272_CR23","unstructured":"NICE. Midostaurin for untreated acute myeloid leukaemia [TA523] [online]. https:\/\/www.nice.org.uk\/guidance\/ta523."},{"key":"1272_CR24","unstructured":"National Institute for Health and Care Excellence. Gilteritinib for treating relapsed or refractory acute myeloid leukaemia: NICE technology appraisal guidance 642 [Internet]. London: NICE; 2020. https:\/\/www.nice.org.uk\/guidance\/ta642\/. Accessed 29 Nov 2021."},{"issue":"1","key":"1272_CR25","doi-asserted-by":"publisher","first-page":"228","DOI":"10.3390\/ijms20010228","volume":"20","author":"C Rautenberg","year":"2019","unstructured":"Rautenberg C, Germing U, Haas R, Kobbe G, Schroeder T. Relapse of acute myeloid leukemia after allogeneic stem cell transplantation: prevention, detection, and treatment. Int J Mol Sci. 2019;20(1):228.","journal-title":"Int J Mol Sci"},{"key":"1272_CR26","unstructured":"Brazier JE, Longworth L. NICE DSU Technical Support Document 8: an introduction to the measurement and valuation of health for NICE submissions. Sheffield: Decision Support Unit, ScHARR; 2011. https:\/\/www.sheffield.ac.uk\/sites\/default\/files\/2022-02\/TSD8-Introduction-to-MVH_final.pdf."},{"issue":"1","key":"1272_CR27","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s12955-018-1013-9","volume":"16","author":"EM Stein","year":"2018","unstructured":"Stein EM, Yang M, Guerin A, Gao W, Galebach P, Xiang CQ, et al. Assessing utility values for treatment-related health states of acute myeloid leukemia in the United States. Health Qual Life Outcomes. 2018;16(1):193.","journal-title":"Health Qual Life Outcomes"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-023-01272-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-023-01272-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-023-01272-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T13:43:20Z","timestamp":1688564600000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-023-01272-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,2]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["1272"],"URL":"https:\/\/doi.org\/10.1007\/s40273-023-01272-9","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,2]]},"assertion":[{"value":"23 March 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have commented on the submitted manuscript and have given their approval for the final version to be published. NA, KM, JH, CA and CN critiqued the clinical effectiveness data reported and literature search conducted by the company. WW, SG, TO and MJ critiqued the mathematical model provided and the cost-effectiveness analyses submitted by the company. WW acts as overall guarantor for the article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment Programme. Please visit the HTA programme website for further project information (). This summary of the ERG report was compiled after NICE issued the FAD. The views and opinions expressed herein are those of the authors and do not necessarily reflect those of NICE or the Department of Health.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"No conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Not applicable.","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}